Eversept Reduces Biotech Exposure
Eversept Partners Significantly Reduces Biotech Holdings Across Five Companies in Q1
Anonymous
Key Points
1
Esperion insider Benjamin Looker sold 11,824 shares on June 17 at an average price of $3.15 (about $37,246 total), leaving him with 667,524 shares valued at roughly $2.10 million.
2
Viridian Therapeutics: Eversept trimmed 60% in Q1, selling 1,068,966 shares and ending with 713,269 shares valued at about $13.95 million.
3
Tyra Biosciences: Eversept reduced its stake by 90.3% in Q1 to 27,055 shares, worth about $1.04 million after selling 251,509 shares.
4
Pharvaris: Eversept’s stake declined 7.3% in Q1 to 406,960 shares, valued at about $11.50 million (roughly 0.62% of the company) after selling 32,217 shares.
5
Vera Therapeutics: Eversept reduced its holding by 29.3% in Q1 to 2,173,286 shares, worth about $87.431 million and representing roughly 4.6% of the portfolio.
Eversept Partners LP sold more than 4.3 million shares across five biotech stocks in the first quarter of 2025, slashing positions in Esperion Therapeutics, Viridian Therapeutics, Tyra Biosciences, Pharvaris, and Vera Therapeutics, according to Ticker Report. The moves point to a broad portfolio rebalancing by the healthcare-focused hedge fund across several late-stage drug developers.
The deepest cut came in Tyra Biosciences, where Eversept sold 251,509 shares — slashing its stake by 90.3% to just 27,055 shares worth about $1.04 million. The firm also trimmed its Viridian Therapeutics position by 60%, selling over one million shares in a single quarter.
Viridian and Vera See the Largest Dollar Exits
Eversept's biggest holding by dollar value is Vera Therapeutics. After selling 895,289 shares, the firm still holds 2,173,286 shares worth roughly $87.4 million — about 4.6% of its total portfolio, per Ticker Report. That makes Vera the firm's largest remaining biotech bet even after a 29.3% reduction.
In Viridian Therapeutics, Eversept sold 1,068,966 shares in Q1. It ended the quarter with 713,269 shares valued at about $13.95 million. That is a 60% cut — the second-largest reduction by percentage among the five stocks.
Tyra Biosciences Position Nearly Wiped Out Entirely
Eversept's exit from Tyra Biosciences was the most dramatic of the group. The firm sold 251,509 shares in Q1, leaving a residual position of just 27,055 shares worth $1.04 million, according to Ticker Report. A 90.3% reduction in a single quarter signals a near-complete exit from the stock.
By contrast, Pharvaris saw the smallest trim. Eversept sold just 32,217 shares — a 7.3% reduction — ending the quarter with 406,960 shares worth about $11.5 million, or roughly 0.62% of the company's total outstanding shares.
Esperion Insider Sells Shares as Eversept Cuts Stake by Half
Eversept cut its Esperion Therapeutics stake by 54.9% in Q1, ending with about 1.74 million shares worth roughly $4.76 million, per Ticker Report. The stock has been under pressure, with shares trading near the low single digits.
Adding to the selling pressure, Esperion insider Benjamin Looker sold 11,824 shares on June 17 at an average price of $3.15, collecting about $37,246. After the sale, Looker held 667,524 shares valued at roughly $2.10 million. Insider sales alongside institutional trimming can signal caution about near-term prospects.
Eversept Also Pulls Back From Non-Biotech Healthcare Names
The biotech selloff was not the only trimming Eversept did in Q1. The firm cut its HealthEquity stake by 72.2% and reduced its HCA Healthcare position by 17.4%, selling 16,645 shares of the hospital giant, according to Ticker Report. The moves suggest a wider pullback from healthcare overall.
On the other side of the ledger, Eversept added 167,949 shares of Liquidia Corporation in Q1 — a 33% increase — bringing its total to 677,392 shares. That selective buying, while broadly selling, suggests the firm is rotating into names it sees as more attractive rather than exiting healthcare entirely.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
21
Articles
14
Reach
35
A
AnonymousAuthor
